Browse by category

Adolescents and young adults in the US are increasingly using popular GLP-1 weight-loss drugs alone or in conjunction with metabolic and bariatric surgery (MBS) to manage obesity, according to a study by UT Southwestern Medical Center (UTSW) researchers. Severe obesity among adolescents and young adults has increased substantially over the past two decades, currently affecting about 9% of people ages 12 to 18. Among adults, the rate of severe obesity increased from 5% to 10%.

Scientists at the Keck School of Medicine of USC, working within the Southern California Superfund Research and Training Program for PFAS Assessment, Remediation and Prevention (ShARP) Center, have uncovered compelling evidence that exposure to perfluoroheptanoic acid (PFHpA), a lesser-known member of the PFAS family of ‘forever chemicals’, is linked to a significantly higher risk and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in adolescents

A University of Toronto study of 1,543 males aged 15 to 35 in Canada and the US has found that those who had used prescription...

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs...

The proportion of adolescents living with overweight or obesity in England has increased by 50% from 2008-2010 (22%) to 2021-2023 (33%),...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Adolescents who perceive themselves as overweight are three times more likely to consider committing self-harm compared to those who do...

After a one-year interdisciplinary therapy programme that included clinical, nutritional, psychological and exercise counselling, a group...

Overweight and obesity are contributing to rising death rates from bowel cancer among people aged 25–49 years in the European Union (EU)...